The Inherited Neurodegenerative Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Inherited Neurodegenerative Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Inherited Neurodegenerative Diseases. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Inherited Neurodegenerative Diseases and features dormant and discontinued products.
GlobalData tracks 29 drugs in development for Inherited Neurodegenerative Diseases by 27 companies/universities/institutes. The top development phase for Inherited Neurodegenerative Diseases is preclinical with 17 drugs in that stage. The Inherited Neurodegenerative Diseases pipeline has 24 drugs in development by companies and five by universities/ institutes. Some of the companies in the Inherited Neurodegenerative Diseases pipeline products market are: Polaryx Therapeutics, Virtus Therapeutics and Azafaros.
The key targets in the Inherited Neurodegenerative Diseases pipeline products market include Ceramide Glucosyltransferase, Copper, and Cyclic GMP-AMP Synthase.
The key mechanisms of action in the Inherited Neurodegenerative Diseases pipeline product include Ceramide Glucosyltransferase Inhibitor with four drugs in Phase III. The Inherited Neurodegenerative Diseases pipeline products include seven routes of administration with the top ROA being Oral and seven key molecule types in the Inherited Neurodegenerative Diseases pipeline products market including Small Molecule, and Gene Therapy.
Inherited Neurodegenerative Diseases overview
Inherited neurodegenerative diseases are a group of disorders that affect the structure and function of neurons, leading to progressive loss of cognitive and motor abilities. Some of these diseases are caused by mutations in single genes, such as Huntington’s disease, while others are influenced by multiple genetic and environmental factors, such as Alzheimer’s disease and Parkinson’s disease. The mechanisms of neuronal death in these diseases are not fully understood, but they often involve abnormal protein aggregation, oxidative stress, inflammation, and mitochondrial dysfunction. Inherited neurodegenerative diseases have no cure, but research is ongoing to find ways to prevent, slow down, or reverse the neuronal damage.
For a complete picture of Inherited Neurodegenerative Diseases’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
